This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

Here at PharmaTell, we have Eyes on FDA Approvals for 2025. Below, we share the monthly Novel Drug and Biologic License Application Approval

Check out the final listings of FDA NDA and BLA approvals for 2024.

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

This week we've had eyes on BioPharma happenings plus a 2023 Top Selling Drugs list.

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.

This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01

This week, the team has been looking at congress planners, earnings call transcripts, and the US FDA.

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.